Arcutis Biotherapeutics Inc
NASDAQ:ARQT

Watchlist Manager
Arcutis Biotherapeutics Inc Logo
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Watchlist
Price: 17.375 USD -0.03% Market Closed
Market Cap: 2.1B USD

Wall Street
Price Targets

ARQT Price Targets Summary
Arcutis Biotherapeutics Inc

Wall Street analysts forecast ARQT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARQT is 23.205 USD with a low forecast of 19.19 USD and a high forecast of 30.45 USD.

Lowest
Price Target
19.19 USD
10% Upside
Average
Price Target
23.205 USD
34% Upside
Highest
Price Target
30.45 USD
75% Upside
Arcutis Biotherapeutics Inc Competitors:
Price Targets
MRNA
Moderna Inc
78% Upside
4584
Kidswell Bio Corporation
68% Upside
ARX
Aroa Biosurgery Ltd
25% Upside
BLAU3
Blau Farmaceutica SA
25% Upside
BAVA
Bavarian Nordic A/S
9% Upside
ARWR
Arrowhead Pharmaceuticals Inc
48% Upside
ZBIO
Zenas Biopharma Inc
75% Upside
ABBV
Abbvie Inc
1% Upside

Revenue
Forecast

Revenue Estimate
Arcutis Biotherapeutics Inc

The compound annual growth rate of Arcutis Biotherapeutics Inc's revenue for the next 3 years is 45%.

N/A
Past Growth
45%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Arcutis Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Arcutis Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ARQT's stock price target?
Price Target
23.205 USD

According to Wall Street analysts, the average 1-year price target for ARQT is 23.205 USD with a low forecast of 19.19 USD and a high forecast of 30.45 USD.

What is Arcutis Biotherapeutics Inc's Revenue forecast?
Projected CAGR
45%

The compound annual growth rate of Arcutis Biotherapeutics Inc's revenue for the next 3 years is 45%.

Back to Top